Edge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage

Pivotal, double-blind, placebo-controlled global study will compare EG-1962 to standard of care oral nimodipine BERKELEY HEIGHTS, N.J., July 29, 2016 -- (Healthcare Sales & Marketing Network) -- Edge Therapeutics, Inc. (EDGE), a clinical-stage biotechno... Biopharmaceuticals, NeurosurgeryEdge Therapeutics, NEWTON 2, subarachnoid hemorrhage, aneurysm, nimodipine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news